Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    CATT
Show Display Options
Rank Status Study
1 Completed Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Other: CATMH intervention
2 Recruiting Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Conditions: Visceral Leishmaniasis;   Human African Trypanosomiasis;   Enteric Fever;   Melioidosis;   Brucellosis;   Leptospirosis;   Relapsing Fever;   Rickettsial Diseases;   HIV;   Tuberculosis;   Malaria;   Amoebic Liver Abscess
Interventions: Device: rk28 ICT;   Device: IT LEISH (rK39);   Device: Immunochromatographic HAT test;   Device: HAT Serostrip;   Device: Card Agglutination Trypanosoma Test (CATT)-10;   Device: Typhidot M;   Device: S. typhi IgM/IgG;   Device: Test-it Typhoid IgM;   Device: Test-it Leptospirosis IgM;   Device: Leptospira IgG/IgM
3 Active, not recruiting Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
Conditions: Neurological Disorders;   Cerebral Malaria;   Bacterial Meningitis;   Central Nervous System Tuberculosis;   Neurosyphilis;   Cryptococcal Meningitis
Interventions: Device: Immunochromatographic HAT tests (DSD);   Device: Card Agglutination Trypanosoma Test;   Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics);   Device: TB 3-marker RDT (Tulip diagnostics);   Device: Cryptococcal Antigen Lateral Flow Assay (Immy)
4 Active, not recruiting
Has Results
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
Condition: Age Related Macular Degeneration
Interventions: Drug: ranibizumab;   Drug: bevacizumab

Indicates status has not been verified in more than two years